Our Take
The industry has finally stopped pretending batch manufacturing scales to personalized medicine; the gap between science and execution is now the only competitive moat that matters.
Why it matters
Cell and gene therapies, GLP-1s, and N-of-1 treatments demand manufacturing models that batch-era plants cannot support. Organizations still betting on capacity expansion are building for yesterday's pipeline.
Do this week
Manufacturing leadership: Audit your process development workflow this week to identify where scientific teams and manufacturing teams first interact, then front-load that conversation to month one of every program.
The Manufacturing Playbook Is Obsolete
The Danaher Bioprocessing Summit in London last month convened executives from Cytiva, Pall, Beckman Coulter Life Sciences, IDBS, and Leica Microsystems alongside biopharma manufacturers and researchers around a single premise: the old model of biomanufacturing no longer fits the medicines being developed.
For decades, bioprocess design was built around high-volume production of standardized therapies. Cell therapies, gene therapies, and precision biologics operate on a different logic. As molecular diversity increases, manufacturers are shifting toward smaller, parallel, and distributed systems that can handle complexity without sacrificing speed.
The shift demands three structural changes. First: manufacturing must become part of the scientific conversation from day one, not a downstream problem solved after research is done. Second: process designs must be data-driven and purpose-built from the start rather than adapted from prior platforms. Third: faster decision-making and new investment models are required because the old cost structures do not support small-batch or patient-specific production.
The summit also surfaced a secondary constraint. Regulatory frameworks governing drug development were built for an earlier era of medicine. As therapies become more complex and more personalized, those frameworks must change. Early engagement and risk-based approaches are helping bring complex therapies to patients faster without compromising rigor, and regulators, according to summit participants, are willing to move faster too.
Data and Prediction Are Now Operational Advantages
Organizations gaining ground are not merely reacting to problems faster. They are anticipating them. Digital twins powered by integrated data enable teams to model outcomes before committing resources, compressing development timelines and reducing risk. Real-time molecular and submolecular-level data shared across interoperable systems enable more precise decision-making at every stage.
Automation and AI are making patient-specific manufacturing operationally feasible for the first time. For years, personalized medicine ran into a hard constraint: you cannot manufacture one patient's therapy using the same approach as a million-dose batch run. Integrating automation, high-throughput experimentation, and AI is changing that equation. These tools enable small-batch and patient-specific manufacturing while improving efficiency, regulatory consistency, and access.
A critical implication: investment in digital infrastructure is no longer discretionary. Organizations without integrated data ecosystems and predictive capabilities will fall behind. Summit speakers emphasized that the science itself is not the limiting factor anymore. The bioindustry already possesses powerful therapeutic capabilities. Execution through manufacturing, regulatory alignment, and supplier collaboration is where the next decade will be decided.
Collaboration and Transparency Are Now Competitive Requirements
A consistent theme across both days of the summit was unavoidable: no single organization can accomplish what is needed alone. Partnerships across academia, industry, and regulators are accelerating the movement of therapies from discovery to approved treatment. Earlier alignment between developers, manufacturers, and regulators is reducing friction and compressing timelines, especially for gene therapies.
What makes these partnerships work is not goodwill but transparency, shared incentives, and data-driven collaboration that keeps everyone oriented around the same outcomes. Organizations making the most progress are treating collaboration as a core capability, not a public relations gesture.
One additional shift: sustainability is moving from corporate commitment into day-to-day supplier decisions. Environmental and social criteria are being integrated into procurement frameworks as verified supplier commitments and shared performance targets. Summit participants agreed that progress toward net-zero goals accelerates when sustainability is wired into commercial relationships rather than managed separately.